Gaucher Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Gaucher Disease stocks.

Gaucher Disease Stocks Recent News

Date Stock Title
Oct 1 SNY Update: Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
Oct 1 SNY Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
Oct 1 SNY Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
Sep 30 SNY Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sep 29 FOLD 'Boring' Amicus Therapeutics Is Making Progress
Sep 28 SNY Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
Sep 27 SNY Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Sep 27 SNY Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Sep 27 SNY Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
Sep 27 SNY Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Sep 27 SNY Sanofi, Regeneron get additional Chinese approval for Dupixent
Sep 27 SNY Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Sep 27 SNY Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Sep 27 SNY Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Sep 27 SNY Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Sep 27 SNY Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Sep 27 SNY FDA, after delay, clears Regeneron and Sanofi drug for COPD
Sep 26 SNY Are Investors Undervaluing Sanofi (SNY) Right Now?
Sep 26 SNY Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
Gaucher Disease

Gaucher's disease or Gaucher disease () (GD) is a genetic disorder in which glucocerebroside (a sphingolipid, also known as glucosylceramide) accumulates in cells and certain organs. The disorder is characterized by bruising, fatigue, anemia, low blood platelet count and enlargement of the liver and spleen, and is caused by a hereditary deficiency of the enzyme glucocerebrosidase (also known as glucosylceramidase), which acts on glucocerebroside. When the enzyme is defective, glucocerebroside accumulates, particularly in white blood cells and especially in macrophages (mononuclear leukocytes). Glucocerebroside can collect in the spleen, liver, kidneys, lungs, brain, and bone marrow.
Manifestations may include enlarged spleen and liver, liver malfunction, skeletal disorders or bone lesions that may be painful, severe neurological complications, swelling of lymph nodes and (occasionally) adjacent joints, distended abdomen, a brownish tint to the skin, anemia, low blood platelet count, and yellow fatty deposits on the white of the eye (sclera). Persons seriously affected may also be more susceptible to infection. Some forms of Gaucher's disease may be treated with enzyme replacement therapy.
The disease is caused by a recessive mutation in the GBA gene located on chromosome 1 and affects both males and females. About one in 100 people in the United States are carriers of the most common type of Gaucher disease. The carrier rate among Ashkenazi Jews is 8.9% while the birth incidence is one in 450.Gaucher's disease is the most common of the lysosomal storage diseases. It is a form of sphingolipidosis (a subgroup of lysosomal storage diseases), as it involves dysfunctional metabolism of sphingolipids.The disease is named after the French physician Philippe Gaucher, who originally described it in 1882.

Browse All Tags